‘Prohibitive’ £3,655 fee for medicinal cannabis licences under review amid protests from campaigners
'The swift response by the government this past month will be undermined if these fees are imposed at the end of the licence process'
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Home Office is reviewing the £3,655 cost of medicinal cannabis licences after it emerged that a new panel to provide patients with access to the schedule 1 drug had received almost no applications.
It is has been reported that fewer than five applications have been received as patients have cast doubt on whether the panel is fit for purpose.
Activists are calling on the government to expedite the process and abolish the fees since there are hundreds of thousands patients who live with conditions such as epilepsy, MS, Crohn's disease and cancer for whom cannabis could potentially relieve suffering.
“The swift response by the government this past month will be undermined if these fees are imposed at the end of the license process,” said Steve Moore, the director of Volteface, a think tank that has called for drug policy reform.
“I would call on the government to abolish these fees with immediate effect.”
After the well-publicised plight of Billy Caldwell caused the government to effectively recognise the medicinal benefits of cannabis, clinicians on the General Medical Council’s specialist register can now apply for a license on behalf of their patients.
For NHS patients, the fee is paid by a hospital trust and it was unclear how proactive individual trusts were being to assist applicants.
The 11-page form, which notes “very few” patients will qualify, must detail all of the drugs prescribed to the person with a “comprehensive” explanation of why they are “genuinely clinically exceptional”.
On Saturday, Sophia Gibson became the first person to be granted a long-term licence for the use of medicinal cannabis in the UK under the new system.
Sir Mike Penning, who chairs the All-Party Parliamentary Group on Medical Cannabis, said it marked a key milestone.
"I hope her success offers hope to the many hundreds who also want access,” he told the BBC.
"Our priority is now rescheduling medical cannabis, so families don't have to use the flawed panel and doctors can prescribe medical cannabis for patients that need it."
Lara Smith, who experiences chronic pain and travels to Amsterdam to access cannabis, told The Times that she would not be applying to the panel due to the costs, which she described as “farcical” and “prohibitive”, serving as a deterrent.
Meanwhile, the mother of Alfie Dingley - who was granted a licenCe following a high-profile campaign - legally brought five months' worth of medicinal cannabis oil into the UK on Tuesday in the first-known such case since the government paved the way for reform.
A Home Office spokesperson said: “The Home Office is committed to reviewing the fees paid for licences that are awarded as a result of the advice of the expert panel. That review will take place urgently and will conclude before summer recess.”
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments